VictorTsu ShihChangMD

Oncology • East Orange, NJ

Attending

Join to view full profile

Dr. Chang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chang's full profile

Already have an account?

Office
385 Tremont Ave
Section Hematology Oncology (111)
East Orange, NJ 07018
Phone+1 973-676-1000

Fax+1 973-395-7096

Education & Training

Clinical Center at the National Institutes of HealthFellowship, Clinical Pharmacology, 1991 - 1992
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1988 - 1990
Good Samaritan Hospital of MarylandResidency, Internal Medicine, 1986 - 1988
Johns Hopkins UniversityResidency, Internal Medicine, 1986 - 1986
Good Samaritan Hospital of MarylandResidency, Internal Medicine, 1985 - 1985
New York University School of MedicineClass of 1983

Certifications & Licensure

NJ State Medical License 1993 - 2025
NY State Medical License 1988 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer Start of enrollment: 2002 Aug 01
Unknown status
Phase 2
A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer Start of enrollment: 2002 Jul 01
Unknown status
Phase 2
Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary Start of enrollment: 2006 Jun 01
Completed
Phase 2
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) Start of enrollment: 2013 Jun 11
Active, not recruiting
Not Applicable
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

31 citations
Neurokinin receptors: relevance to the emerging immune system.
Helen S. Kang, Katarzyna A. Trzaska, Kelly E. Corcoran, Victor T. Chang, Pranela Rameshwar
Archivum Immunologiae Et Therapiae Experimentalis. 2004-09-01
27 citations
Clinician perceptions of care difficulty, quality of life, and symptom reports for lung cancer patients: an analysis from the Symptom Outcomes and Practice patterns (S...
Heidi A. Hamann, Ju Whei Lee, Joan H. Schiller, Leora Horn, Lynne I. Wagner
Journal of Thoracic Oncology. 2013-12-01
118 citations
Why are missing quality of life data a problem in clinical trials of cancer therapy
Diane L. Fairclough, Harriet F. Peterson, Victor T. Chang
Statistics in Medicine. 1998-03-15

Professional Memberships

American Society of Clinical Oncology - ASCO
Member